Cova322 (Anti-IL-17 & TNF-Alpha)
Product Specifications
Target
TNF-alpha
Applications
Apoptosis
Additionnal Information
Cova322 is a bispecific FynomAb targeting TNF and IL-17A, created by fusing a small anti-IL-17A Fynomer to the anti-TNF antibody adalimumab. It shows potent inhibition of TNF and IL-17A in vitro and in vivo, offering potential benefits for inflammatory disease treatment. M.W 161.9 kDa.
Storage Conditions
-80°C (avoid freeze-thaw cycles)
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC680029-100 1x 100 µL
Fibronectin (TV-1), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040669-500 1x 500 µL
P27 / KIP1 (SX53G8), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470525-100 1x 100 µL
CD63 (MX-49.129.5), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740257-100 1x 100 µL
Cytokeratin, HMW (AE-3), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details